News

Reports

Notices

News

Number Title Author Date
Notice
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
alteogen | 2023.09.06 | Votes 0 | Views 292
alteogen 2023.09.06
Notice
Hyaluronidase : A new way to be excluded from drug price negotiations under IRA
alteogen | 2023.08.01 | Votes 0 | Views 515
alteogen 2023.08.01
Notice
Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products
alteogen | 2023.01.06 | Votes 0 | Views 2189
alteogen 2023.01.06
Notice
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients
alteogen | 2023.01.06 | Votes 0 | Views 1310
alteogen 2023.01.06
Notice
Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products
alteogen | 2023.01.06 | Votes 0 | Views 1234
alteogen 2023.01.06
Notice
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme™ Technology
alteogen | 2023.01.06 | Votes 0 | Views 1305
alteogen 2023.01.06
Notice
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of Its Hybrozyme™Technology
alteogen | 2023.01.06 | Votes 0 | Views 1008
alteogen 2023.01.06
29
Merck to Manufacture Next-Generation Biotherapeutics for Alteogen
alteogen | 2023.01.06 | Votes 0 | Views 1278
alteogen 2023.01.06
28
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020
alteogen | 2023.01.06 | Votes 0 | Views 794
alteogen 2023.01.06
27
Alteogen Inc. obtained IND approval for a clinical trial in Korea for Eylea Biosimilar (ALT-L9)
alteogen | 2019.05.22 | Votes 0 | Views 4181
alteogen 2019.05.22
26
Alteogen applies for P1 trial for Eylea biosimilar
alteogen | 2019.02.28 | Votes 0 | Views 2857
alteogen 2019.02.28
25
Alteogen Inc. Becomes First Mover for Eylea Biosimilar with securing global competitiveness by registering patent
alteogen | 2019.01.04 | Votes 0 | Views 3013
alteogen 2019.01.04
24
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
alteogen | 2018.12.04 | Votes 0 | Views 2928
alteogen 2018.12.04
23
Alteogen's Kadcyla biobetter gains edge in gastric cancer with FDA orphan designation
alteogen | 2018.08.17 | Votes 0 | Views 2697
alteogen 2018.08.17
22
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer
alteogen | 2018.08.07 | Votes 0 | Views 2660
alteogen 2018.08.07
21
Alteogen develops antibody transferring IV to SC injection
alteogen | 2018.07.30 | Votes 0 | Views 2340
alteogen 2018.07.30
20
Alteogen, Lynkogen targeting large NASH, diabetes markets in cross-royalty collaboration
alteogen | 2018.07.11 | Votes 0 | Views 2160
alteogen 2018.07.11